Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Provided By GlobeNewswire
Last update: Apr 3, 2025
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
Read more at globenewswire.com
